Puma Biotechnology | PBYI - Debt


Puma Biotechnology reported $89.06M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Exelixis USD 176.46M 3.38M Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 40.41M 855K Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Moderna USD 734M 7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025